Background: Primary mediastinal germ cell tumors (GCTs) are rare in children and still represent a challenge for both adult and pediatric oncologists because of their worse outcome compared to their gonadal counterpart.
Procedure: Prospectively collected data concerning patients enrolled in the Italian Association of Pediatric Haematology and Oncology study on malignant GCTs (AIEOP TCGM 2004) protocol for the treatment of GCTs were analyzed. Patients with malignant mediastinal primary GCTs were included in this study. Data regarding patients with newly diagnosed mediastinal teratoma were also collected.
Results: From 2005 to 2013, 20 children diagnosed with mediastinal GCTs were registered in AIEOP TCGM 2004 protocol. With a median follow-up of 89 months (range 35-123), the overall survival (OS) and event free survival (EFS) rates were 100% for teratoma and 90% for malignant GCTs.
Conclusions: We confirm the favorable outcome of children affected by mediastinal teratoma and malignant GCTs. For malignant tumors, further studies on the clinical characteristics and genetic signatures on tumor samples might be necessary to better understand differences observed in high-risk patients and to assist the development of more effective treatment for this subgroup.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/pbc.25895 | DOI Listing |
Ann Cardiol Angeiol (Paris)
January 2025
Cardiology Department, Ibn Rochd Hospital University, Casablanca, Morocco.
Introduction: Mature teratomas, a diverse group of germ cell tumors, rarely present with complications such as rupture.
Case Presentation: We present a case of a 27-year-old male who was admitted to our hospital with acute dyspnea. A tamponade was diagnosed and the patient underwent a pericardial puncture.
Arch Gynecol Obstet
January 2025
Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric & Gynecologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Purpose: To provide a comprehensive understanding and propose a strategy for the management of extragonadal malignant germ cell tumors (EMGCTs) arising from extracranial and nonvaginal sites.
Methods: We retrospectively reviewed the cases of 12 patients with EMGCTs arising from extracranial and nonvaginal sites treated in our center over the past 38 years. Data on clinicopathological characteristics, treatment modalities, and follow-up information were analyzed.
Hinyokika Kiyo
December 2024
The Department of Pathology, Yokohama City University Hospital.
A 28-year-old male presented to his physician with a chief complaint of fever and cough. Contrastenhanced computed tomography revealed a 17×16×8 cm heterogeneous tumor in the anterior mediastinum, as well as right heart and inferior vena cava compression due to the tumor. He was referred to our hospital for close examination and treatment.
View Article and Find Full Text PDFZhonghua Er Ke Za Zhi
January 2025
Department of Medical Oncology, Pediatric Oncology Center,Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, National Key Clinical Discipline of Pediatric Oncology,Laboratory for Clinical Medicine, Capital Medical University, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing100045, China.
Radiol Case Rep
February 2025
Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Seminoma is a malignant germ cell tumor that primarily develops in the testis but can occur in other extragonadal areas, most commonly the mediastinum and retroperitoneum. While generally offering a favorable prognosis, seminomas can sometimes clinically present with misleading characteristics resulting in delayed diagnosis. In this article, we report the case of a 31-year-old male diagnosed with grade IIIC intermediate risk testicular seminoma cTxN3M1bSx, who presented initially with a palpable cervical mass.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!